Mekinist

Trametinib, the active ingredient in Mekinist, is a MEK inhibitor presented as an oral tablet for oral use. It targets cancers that harbor BRAF V600E/K mutations, including certain melanomas and non‑small cell lung cancers. GNH USA supplies Mekinist as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Mekinist acts on the MAPK/ERK pathway in tumors with specific BRAF mutations. - BRAF V600E/K mutation‑positive unresectable or metastatic melanoma: improves progression‑free survival when used alone or with dabrafenib. - BRAF V600E/K mutation‑positive metastatic non‑small cell lung cancer: provides targeted therapy to delay disease progression.

Adverse reactions may occur with trametinib therapy.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Diarrhea: frequent loose stools. - Fatigue: persistent tiredness. - Nausea: upset stomach and urge to vomit. - Peripheral edema: swelling of the lower extremities. - Acneiform dermatitis: acne‑like lesions on the face or trunk.

Serious or Rare Side Effects: - Interstitial lung disease: breathing difficulties and cough. - Cardiac dysfunction: reduced left‑ventricular ejection fraction. - Severe hepatic injury: elevated liver enzymes and jaundice. - Ocular toxicity: blurred vision or retinal disorders. - Febrile neutropenia: fever with low white‑blood‑cell count.

Before initiating trametinib, clinicians should consider several safety measures. - Cardiac monitoring: assess baseline and periodic ejection fraction. - Hepatic assessment: check liver function tests before and during therapy. - Ocular evaluation: perform eye examinations for visual changes. - Infection vigilance: monitor for signs of infection, especially if neutropenia occurs. - Pregnancy and lactation: avoid use in women who are pregnant or breastfeeding due to unknown risk. - Store at room temperature: keep tablets in the original container, protect from moisture and light.

Trametinib may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce trametinib exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase trametinib concentrations and toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may require INR monitoring. - Other antineoplastic agents: overlapping toxicities may need dose adjustments. - Oral contraceptives: reduced efficacy possible, consider alternative contraception.